Login

Unity Biotechnology, Inc. 8-K SEC Filings

Filed On Filing
26 Sep 2025 8-K: Termination of a Material Definitive Agreement; Material Modification to Rights of Security Holders

This LEASE TERMINATION AGREEMENT AND AMENDMENT (this “Agreement”) is entered into as of September 24, 2025 (the “Effective Date”) by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company (“Landlord”), and UNITY ...

19 Sep 2025 8-K: Submission of Matters to a Vote of Security Holders

On September 18, 2025, Unity Biotechnology, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). As of the close of business on July 25, 2025, the record date for the Special Meeting (the “Record Date”), t...

22 Jul 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

THIS PURCHASE AGREEMENT (this “Agreement”) is made as of July 22, 2025, by and between the purchaser listed on Exhibit A attached hereto (the “Purchaser”) and Unity Biotechnology, Inc., a Delaware corporation (the “Company”).

30 Jun 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation +1 more

This Plan of Complete Liquidation and Dissolution (the “Plan”) is intended to constitute a plan of distribution under Section 281(b) of the General Corporation Law of the State of Delaware (“DGCL”) and accomplish the complete liquidation...

20 Jun 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On June 18, 2025, Unity Biotechnology, Inc. (the “Company”) received a notification from The Nasdaq Stock Market (“Nasdaq”) that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1....

05 May 2025 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

22 Apr 2025 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results...

04 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

On April 3, 2025, Paul L. Berns informed the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) of his resignation as a member of the Board of the Company, and all of the committees of the Board on w...

24 Mar 2025 8-K: Other Events

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population

17 Mar 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On March 14, 2025, UNITY Biotechnology, Inc. (“Unity” or the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that its stockholders’ equity as reported in its Annual Report on Form 10-K had falle...

10 Mar 2025 8-K: Changes in Control of Registrant; Other Events

SAN FRANCISCO, Calif., March 10, 2025 – UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vi...

07 Mar 2025 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., March 7, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results ...

06 Jan 2025 8-K: Other Events

SAN FRANCISCO, Calif., January 6, 2025 - UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with...

04 Nov 2024 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., November 4, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial resul...

06 Aug 2024 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., August 6, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results...

21 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

On June 21, 2024, Unity Biotechnology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more det...

14 May 2024 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results f...

15 Apr 2024 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results...

20 Mar 2024 8-K: Non-Reliance on Previously Issued Financial Statements

On March 19, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of UNITY Biotechnology, Inc. (the “Company”), after consultation with management, determined that the Company incorrectly classified its warrants (t...

13 Nov 2023 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., November 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial resu...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support